{"version":"1.0","provider_name":"hollandbio","provider_url":"https:\/\/www.hollandbio.nl\/en\/","title":"BiosanaPharma\u2019s biosimilar phase I study successful - hollandbio","type":"rich","width":600,"height":338,"html":"<blockquote class=\"wp-embedded-content\" data-secret=\"dyN520W8jl\"><a href=\"https:\/\/www.hollandbio.nl\/en\/nieuws\/biosanapharmas-biosimilar-phase-i-study-successful\/\">BiosanaPharma\u2019s biosimilar phase I study successful<\/a><\/blockquote><iframe sandbox=\"allow-scripts\" security=\"restricted\" src=\"https:\/\/www.hollandbio.nl\/en\/nieuws\/biosanapharmas-biosimilar-phase-i-study-successful\/embed\/#?secret=dyN520W8jl\" width=\"600\" height=\"338\" title=\"&#8220;BiosanaPharma\u2019s biosimilar phase I study successful&#8221; &#8212; hollandbio\" data-secret=\"dyN520W8jl\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\" class=\"wp-embedded-content\"><\/iframe><script>\n\/*! This file is auto-generated *\/\n!function(d,l){\"use strict\";l.querySelector&&d.addEventListener&&\"undefined\"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!\/[^a-zA-Z0-9]\/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret=\"'+t.secret+'\"]'),o=l.querySelectorAll('blockquote[data-secret=\"'+t.secret+'\"]'),c=new RegExp(\"^https?:$\",\"i\"),i=0;i<o.length;i++)o[i].style.display=\"none\";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute(\"style\"),\"height\"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):\"link\"===t.message&&(r=new URL(s.getAttribute(\"src\")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener(\"message\",d.wp.receiveEmbedMessage,!1),l.addEventListener(\"DOMContentLoaded\",function(){for(var e,t,s=l.querySelectorAll(\"iframe.wp-embedded-content\"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute(\"data-secret\"))||(t=Math.random().toString(36).substring(2,12),e.src+=\"#?secret=\"+t,e.setAttribute(\"data-secret\",t)),e.contentWindow.postMessage({message:\"ready\",secret:t},\"*\")},!1)))}(window,document);\n\/\/# sourceURL=https:\/\/www.hollandbio.nl\/wp-includes\/js\/wp-embed.min.js\n<\/script>\n","description":"BiosanaPharma, an Australian\/Dutch biotech company, today announced the successful outcome of a comparative phase I clinical study in healthy volunteers of BP001, a biosimilar candidate to Xolair\u00ae (omalizumab). The study was conducted in Australia, with 84 healthy male volunteers. The results of the study show that bioavailability, safety, tolerability and immunogenicity of BP001 are comparable [&hellip;]","thumbnail_url":"https:\/\/www.hollandbio.nl\/wp-content\/uploads\/2025\/01\/hb-opengraph_illu.png","thumbnail_width":1200,"thumbnail_height":675}